insights_auto
Why is 524494 down ၃.၅၁%?
Dive Deeperchevron_right
524494:BOM
IPCA Laboratories Ltd
၁,၈၄၅.၀၀ ₹
arrow_downward
-၃.၅၁%(-၆၇.၂၀) 1D
အောက် ၁၆, GMT+၅:၃၀ ၁၅:၃၀:၀၀ · INR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 524494...
Open
၁,၉၁၃.၉၅ ₹
High
၁,၉၁၃.၉၅ ₹
Low
၁,၈၁၂.၆၀ ₹
Mkt. cap
ဋေ ၄.၆၈ သ
Avg. vol.
၂.၇၉ သောင်း
Volume
၀.၀၀
Dividend
၀.၃၃%
Quarterly dividend
၁.၅၀ ₹
Ex-dividend date
၂၀၂၆ ဩ ၇
P/E ratio
၃၅.၇၄
52-wk high
၂,၀၃၉.၃၀ ₹
52-wk low
၁,၂၅၂.၉၅ ₹
EPS
၅၁.၆၃ ₹
Shares outstanding
၁၂.၆၄ ကုဋေ
No. of employees
၂ သောင်း
Open
၁,၉၁၃.၉၅ ₹
High
၁,၉၁၃.၉၅ ₹
Low
၁,၈၁၂.၆၀ ₹
Mkt. cap
ဋေ ၄.၆၈ သ
Avg. vol.
၂.၇၉ သောင်း
Volume
၀.၀၀
Dividend
၀.၃၃%
Quarterly dividend
၁.၅၀ ₹
Ex-dividend date
၂၀၂၆ ဩ ၇
P/E ratio
၃၅.၇၄
52-wk high
၂,၀၃၉.၃၀ ₹
52-wk low
၁,၂၅၂.၉၅ ₹
EPS
၅၁.၆၃ ₹
Shares outstanding
၁၂.၆၄ ကုဋေ
No. of employees
၂ သောင်း
News stories
From web sources and news partners
Simply Wall Street
·
ပြီးခဲ့သည့် ၁၀ မိနစ်
What Viasat Doubters Got Wrong
The Fintech Times
·
ပြီးခဲ့သည့် ၅၀ မိနစ်
First Digital to List on Nasdaq via SPAC Deal at $250m Valuation
Yahoo Finance
·
ပြီးခဲ့သည့် ၁ နာရီ
Anthropic IPO Buzz Has Investors Watching Nasdaq Stock And ECM Fee Winners
Profile
Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The company manufactures and markets more than 350 finished-dosage formulations and around 80 active pharmaceutical ingredients, covering therapeutic areas that include pain management, rheumatology, antimalarials, cardiovascular medicine, dermatology and anti-diabetics, and has an emerging biosimilars business. Its products are sold in over 100 countries, and it is one of India's larger API exporters, supplying more than 70 countries.
Ipca is one of the largest global suppliers of the antimalarials hydroxychloroquine and chloroquine, as well as of APIs such as atenolol, chlorthalidone, losartan and metoprolol. Since 2023, it has held a majority stake in Unichem Laboratories. The company is listed on the BSE and the National Stock Exchange of India, and reported consolidated revenue of ₹9,646 crore in the financial year ended 31 March 2026. Wikipedia
About IPCA Laboratories Ltd